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Two of the most important mechanisms controlling vascular
function, ranging from regulation of diameter and structure to
protection against atherosclerosis, are endothelial production of nitric
oxide and gap junction communication between cells in the vascular
wall. Nitric oxide, primarily produced by the enzyme endothelial nitric
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guanylate cyclase(sGC)-cGMPsignaling [1,2], and is therefore important
for vasodilation, particularly in larger arteries [3]. It is also essential for
angiogenesis, arteriogenesis, and opposition of atherogenic changes in
the vascular wall [4]. In addition to signaling through sGC-cGMP, nitric
oxide has the potential to nitrosylate nearby proteins on cysteine
residues [5–7], which is a major mechanism for controlling protein
function [8]. Gap junctions are essential to the spread of dilation and
constriction along the length of the artery, are involved in vasomotionFig. 1. Model for the interaction of the nitric oxide system with vascular connexins. Nitric ox
1) activation of endothelial cells by shear stress or agonists such as bradykinin leading to activa
α1-adrenergic stimulation followed bymovement of IP3 throughmyoendothelial gap junctions
panel), and 3) activation of nNOS in nitrergic nerves. Nitric oxide action includes S-nitrosylati
Cx43-containing gap junctions in theMEJ, and possibly at other sites in the vascular cells. Nitric o
while it increasesdenovo formation of Cx40-containing gap junctions in a cGMP-dependentman
containedwithin the caveolae (illustrated in CAVEOLAE panel). Cx37 interaction decreases eNOS
Both eNOS and Cx43 have been found to bind directly to caveolin-1. Although connexins are sho
connexin isoform bind to form heteromeric and/or heterotypic gap junction channels. * indicatand myogenic tone, and are implicated in non-nitric oxide, non-
prostacyclin endothelium-dependent vasodilation in many vascular
beds, now usually termed endothelium-dependent hyperpolarization
(EDH) [9,10]. Evidence is accumulating that nitric oxide signaling and
gap junction communication are not separate pathways, but rather
interdependent functions. The key constituents of these pathways,
eNOS and connexins, respectively, both associate with the caveolar
protein caveolin-1 and their individual activity and expression inﬂuence
each other acutely and in disease states. This review will examine theide production can be stimulated by several mechanisms, including, but not limited to:
tion of eNOS and possibly nNOS, 2) activation of endothelial eNOS through smooth muscle
(MEJs) and release of Ca++ from the endothelial sarcoplasmic reticulum (illustrated inMEJ
on of Cx43 (and possibly other connexins and Panx1), which increases the open state of
xide also inhibits Cx37 channel conductance in a generally non-cGMP-dependentmanner,
ner. eNOS, Cx37, andCx40 can exist in a complex, but it is not clearwhether this complex is
activity,while Cx40 expression is essential for proper expression of eNOS at themembrane.
wn in homomeric/homotypic gap junction channels, it is quite possible that more than one
es tissue variability in expression. Dashed lines indicate possible routes for nitric oxide.
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may affect vascular function in health and disease. In addition, the
potential relationship of the newly discovered pannexin channels with
the nitric oxide pathway will be explored (Fig. 1).
2. Nitric oxide alters gap junction function
It has been demonstrated in both cultured endothelial cells and in
intact arterioles in vivo that exogenously applied nitric oxide, particu-
larly in high doses, can acutely alter gap junction function [11–15]. In
addition, some evidence indicates that endogenously produced nitric
oxide also effects gap junction function [16], particularly under
conditions when nitric oxide production is high. However, it is unclear
from the existing evidence which vascular connexin isoforms (Cx45,
Cx43, Cx40, Cx37, Cx32) are involved and which gap junction locations
[endothelial–endothelial, smooth muscle–smooth muscle, myoen-
dothelial (MEJ)] are targeted.
2.1. Evidence in cultured cells
In cultured endothelial cells, nitric oxide donors acutely alter gap
junction coupling, but the effects are variable depending on whether
gap junctions are newly forming or stable. In cultured HUVECs (human
umbilical endothelial cells), inhibition of NOS or superoxide had no
effect on newly forming gap junction coupling, but addition of a nitric
oxide donor enhanced the formation of coupling, except at very high
doses, and was found to be dependent upon cGMP and cAMP-PKA [12].
The cGMP pathway has the ability to stimulate the cAMP-PKA
pathway by preventing the degradation of cAMP through phospho-
diesterase inhibition [17]. The same study further showed that in
HeLa cells (a cancer cell line that does not endogenously express
connexins, which can be transfected to express various connexins),
Cx40 is responsible for the NO-dependent enhancement in coupling, as
only Cx40homomeric/homotypic or Cx40–Cx37homomeric–heterotypic
channels were responsive to NO. Trafﬁcking of Cx40 to the
membrane was enhanced in HUVECs by nitric oxide donors, in a
cAMP-PKA-dependent manner. These data suggest that NO regulates
Cx40 translocation and function, and the authors speculate that it
may do so through phosphorylation of Cx40 on a putative PKA
phosphorylation site or effects on microtubular transport [12].
In cultured endothelial cells, stable gap junctions are also affected by
exogenous nitric oxide donors, which decrease dye coupling (i.e., gap
junction permeability) in HUVECs [11] and decrease electrical coupling
in microvascular endothelial cells [13]. The study performed with
microvascular endothelial cells further found that the reduction in gap
junction communication was dependent upon Cx37, but not Cx40 or
Cx43, and could not be explained by superoxide or peroxynitrite
elevation. Serine phosphorylation of Cx37 was not required. In both
studies, the reduction in gap junction communicationwas independent
from cGMP. These studies suggest that classic nitric oxide-induced
cGMP-PKG signaling is not involved in alteration of coupling, and opens
the possibility that the other mechanism of nitric oxide signaling,
namely S-nitrosylation, is regulating Cx37 and endothelial cell coupling.
This is a very real possibility given that Cx43 can be nitrosylated [16].
However, there is currently no evidence in any cell type as to whether
Cx37alsoundergoes thismodiﬁcation andwhat effect it has on function.
In co-cultured endothelial and smooth muscle cells, an important in
vitro model for studying gap junction communication at the myoen-
dothelial junction (MEJ), nitric oxide has been shown to enhance MEJ
communication [16]. This study found Cx43 and eNOS to be enriched at
the MEJ both in co-culture and in multiple types of intact arteries,
although vessels isolated from different tissue beds had unequal
distribution of eNOS at the MEJ. In both co-culture and intact arteries,
Cx43 was constitutively S-nitrosylated on cysteine271. This modiﬁca-
tion appears to be responsible for the open state of Cx43-containing gap
junctions because denitrosylation of Cx43 speciﬁcally at the MEJcorrelates with a reduction of communication, as evidenced by the
restricted movement of IP3 from smooth muscle to endothelium upon
phenylephrine stimulation. Moreover, enhancing Cx43 nitrosylation,
through inhibition or genetic knockdown of the enzyme GSNOR, an
enzyme which denitrosylates Cx43, led to greater communication
through the MEJ measured directly in vitro and indirectly in intact
murine thoracodorsal arteries. In this study, S-nitrosylation of Cx40, a
connexin also found at theMEJ in thismodel [18],wasnot detected. This
body of work provides evidence that nitric oxide regulates Cx43 gap
junction permeability and heterocellular communication through the
MEJ (and potentially at other sites in the intact artery) within the
resistance vasculature. The unequal distribution of eNOS in different
tissue beds at the MEJ may provide a unique tissue-speciﬁc control
mechanism for S-nitrosylation of Cx43 composed gap junctions at the
MEJ and new insight as to how various tissue beds regulate local
blood ﬂow.
Collectively, data from cell culture indicate that exogenous nitric
oxide can enhance Cx40 incorporation into the endothelial cell
plasma membrane through cGMP-dependent signaling, can impair
Cx37-dependent communication between endothelial cells without
reliance on cGMP signaling, and endogenous nitric oxide can enhance
Cx43-dependent communication at the MEJ through S-nitrosylation.
Thus, three of the major vascular connexins are all affected by
exogenous or endogenous nitric oxide though at least two different
mechanisms. The effects on Cx37 and Cx43 were found to be rapid and
reversible without changes in expression, supporting a mechanism
involving post-translational modiﬁcation. Notably, S-nitrosylation is a
post-translational mechanismworthy of investigation in the regulation
of Cx37, as othermajormechanisms have been largely unsupported. It is
also possible that phosphorylation of connexins or their protein binding
partnersmay play a role in nitric oxide-mediated regulation, but there is
little evidence regarding the sites of phosphorylation or the kinases
involved. Even though cultured cells have substantial differences from
healthy intact vascular cells [19], the effects of nitric oxide on the
connexins show consistencywith intact artery function, as explained in
the next section.
2.2. Evidence in vivo
In vivo, gap junction function can typically be assessed bymeasuring
conduction of vasoconstriction along the length of an artery/arteriole,
conduction of vasodilation along the length of an artery/arteriole, or
MEJ-mediated vasodilation. This latter function can be tested by
assessing EDH-mediated vasodilation in vessels shown to utilize gap
junction communication for this response, or by assessing reactive
vasodilation in response to phenylephrine stimulation of smooth
muscle, which requires functional MEJ [20–24]. It is not always clear,
however, which connexin isoforms are responsible for each of these
functions within a given vessel type or among species. It is certainly
possible and likely that each gap junction site (EC-EC, SMC–SMC, MEJ)
containsmultiple connexins possibly in heteromeric and or heterotypic
conﬁgurations. These uncertainties complicate the interpretation of in
vivo data.
In vivo, both endogenous nitric oxide (as evidenced by NOS
inhibitors or genetic deletion of eNOS) or exogenously added nitric
oxide donors, impair the spread of vasoconstriction along mouse
cremaster arterioles [14,15]. This conducted vasoconstriction apparent-
ly relies on gap junctions between smooth muscle cells, and does not
seem to involve Cx40 (as evidenced by a lack of effect in CX40−/−
mice) [14]. The inhibitory effect of nitric oxide was only partially
dependent upon cGMP signaling. This means that other effects of nitric
oxide, such as S-nitrosylation are possible mechanisms.
Sepsis has also been shown to impair conducted vasoconstriction in
mouse cremaster arterioles, in a reversible manner that was partially
nitric oxide dependent and fully tyrosine phosphorylation dependent
[15]. The source of nitric oxide in septic arterioles is largely nNOS, as this
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nNOS (but not eNOS or iNOS) eliminates the nitric oxide-induced
impairment in conducted vasoconstriction [25]. The conducted
response in these vessels was found to be dependent upon Cx37
because genetic deletion eliminated conducted vasoconstriction.
However, it is possible that other connexins are also involved given
that genetic deletion of one connexin usually affects expression of other
connexins [26–30]. In these arterioles, the nitric oxide-induced
reduction in conducted vasoconstriction was not dependent upon
cGMP. So, like cultured endothelial cells, communication through
Cx37-containing gap junctions is likely altered by nitric oxide through
alternative mechanisms, such as S-nitrosylation.
The effect of nitric oxide on conducted vasodilation is less consistent.
One study indicated that blockade or addition of nitric oxide had no
effect on conducted vasodilation in mouse cremaster arterioles in vivo,
suggesting that nitric oxide does not alter communication through
endothelial gap junctions [14]. Another study performed in the same
vascular bed, showed that histamine, an inﬂammatory factor that
induces vasodilation through eNOS-dependent nitric oxide production
[31], impaired conduction of vasodilation inmouse cremaster arterioles
[32]. This impairment was dependent upon the presence of eNOS and
the activation of the cGMP pathway. The reason for the differences in
these studies is not clear, but may be related to speciﬁc effects of
histamine addition in a later study.
Examining the role of nitric oxide in modifying MEJ communication
in vivo is particularly challenging. This is because EDH-mediated
vasodilation is determined by blocking nitric oxide synthases
(with inhibitors such as L-NAME) and cyclooxygenase, and examining
the remainingdilation response. Therefore the role of endogenous nitric
oxide on EDH-mediated vasodilation cannot be assessed. In addition,
EDH-mediatedvasodilationmaydependonmechanisms other thangap
junction communication, such as diffusible factors [9], which may be
experimentally difﬁcult to separate due to overlap in their signaling
pathways (i.e., involvementof KCa channels) [33], the lack of speciﬁc gap
junction inhibitors (although connexin-mimetic peptides may be
speciﬁc) [9], and the unclear identity of the MEJ connexins. Moreover,
MEJ communication has been observed under some in vivo experimen-
tal conditions [34] but not others [35,36]. Direct in vivo evidence is,
therefore, lacking. Evidence in isolated vessels has indicated that
exogenous nitric oxide can inhibit EDH attributed to a diffusible
factor like epoxyecosotrienoic acids (EETs) [37,38], but has no effect
on EDH-mediated dilation in mouse superior mesenteric artery [39], a
vessel which has functional MEJ communication (as indicated by
heterocellular dye coupling) [24,39] and the EDH response is at least
partially attributed to gap junction communication in branches of this
artery [24]. This very limited evidence suggests that exogenous nitric
oxide does not alter this type of MEJ-mediated function.
Collectively, in vivo evidence is consistent with cell culture
evidence in that elevation of nitric oxide impairs gap junction
communication conducted through Cx37-containing channels, prob-
ably located at homocellular junctions. In vivo effects of nitric oxide on
Cx40- and Cx43-containing channels are not clear.
3. Interrelationship of eNOS and gap junctions
3.1. Loss of eNOS affects gap junction communication
The effect of eNOS presence on connexins and gap junction
communication has been studied in eNOS−/− mice. There is some
evidence that loss of eNOS upregulates gap junction communication in
certain arteries. With regard to conduction of vasodilation, eNOS
knockout mice have normal conduction in cremaster arterioles,
suggesting that endothelial cell gap junctions are not affected by the
loss of eNOS [32]. Conversely, conductedvasoconstriction is enhanced in
eNOS−/− mice [14], suggesting that smooth muscle cell gap junction
communication is enhanced.In male eNOS−/− mice the EDH-dependent dilation is increased
in isolated skeletal muscle arterioles [40] and mesenteric arteries
[41–43]. This suggests the possibility of enhanced MEJ coupling. One
of these studies did ﬁnd that the enhanced EDH response was blocked
by the non-selective gap junction inhibitor 18alpha-glycyrrhetinic
acid supporting this concept [43]. It should be noted that not all
studies have found enhanced EDH-dependent vasodilation in mes-
enteric arteries in eNOS −/− mice. One study found no EDH-
mediated responses in these arteries in either wild-type or eNOS−/−
[44], and another found a decline [45].The loss of eNOS does not seem
to effect connexin regulation at the transcriptional level because
connexin mRNA (Cx37, Cx40, Cx43, Cx45) expression is similar in the
mesenteric arterial vasculature of both wild-type and eNOS knockout
mice [46]. Therefore, it is likely that post-translational mechanisms
are responsible for alterations in gap junction coupling.
It is not clear whether the enhanced gap junction communication,
as evidenced in most studies, with the deletion of eNOS is due to loss
of the inhibitory effect of nitric oxide on gap junction communication,
or due to a loss of interaction between eNOS and connexin proteins.
The direct interaction between these proteins is highlighted in the
next section.
3.2. Loss of connexins affects eNOS expression and function
The expression and localization of eNOS are partially dependent
upon the expressionof gap junctionproteins. It has recently been shown
that if Cx40 is absent (Cx40−/−mice), with a coincident reduction in
Cx37, then aortic eNOS expression and function are impaired [27]. This
reduction in eNOS is post-transcriptional, as eNOSmRNA is comparable
in Cx40−/− andwild-type aorta. Moreover, Cx40, Cx37, and eNOSmay
form a protein complex, as evidenced byboth immunoprecipitation and
in situ proximity ligation assay, indicating localization of this complex at
the borders of aortic endothelial cells.
It is likely that eNOS and Cx37 interact directly because the C-termof
Cx37 contains a binding motif for eNOS [47]. The region of eNOS with a
Cx37 binding motif lies in the same region that binds to caveolin-1, a
negative regulator of eNOS activity [48–50] and a scaffolding protein
that directs the formation of caveolae [51–55]. In cultured cells, a
peptide corresponding to the eNOS bindingmotif reduces Cx37 channel
conductance, suggesting that eNOSmay be a negative regulator of Cx37
channel activity [47]. In culturedendothelial cells, not only are eNOS and
Cx37 shown to associate, but knockdown of Cx37 with RNAi results in
increased eNOS activity and NO production, indicating that like
caveolin-1, Cx37 may be a negative regulator of eNOS [47]. The results
from cultured endothelial cells must be interpreted with caution,
however, because cultured endothelial cells contain 10–1000-fold less
caveolae than endothelial cells within intact vessels [56], coincident
with relocation of caveolin-1 from the cell membrane to the perinuclear
region [47]. Because both eNOS and connexins can localize to lipid rafts
and caveolae and physically associate with caveolin-1 [57–61], the loss
of interaction with caveolin-1 may alter the dynamics of eNOS and its
binding patterns. For example, the absence of caveolin-1 may promote
binding of Cx37 to eNOS. Despite the limitations of cell culture data, the
physical association of eNOS, Cx37, and Cx40 in themembrane of aortic
endothelial cells in vivo [27], suggest that cell culture data is at least
partly consistent with an interaction between these proteins in vivo.
3.3. Disruption of caveolae effects both nitric oxide signaling and gap junction
function
In unstimulated endothelial cells, caveolin-1 binds to eNOS and
suppresses its activity [48–50]. Upon stimulation, calcium-calmodulin
binds to eNOS, and caveolin-1 dissociates to allow full activationof eNOS
[56,62,63]. If caveolin-1 is absent, there is loss of normal endothelial
caveolar structures and failure of proper regulation of eNOS function
[52,53,64,65]. Like eNOS, connexins have been found to associate with
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associate with caveolin-1 in 293T cells transfected with both proteins
[57], and later discovered to directly interact with caveolin-1 in
keratinocytes [66]. Since this original discovery, both Cx43 and Cx40
have been found to co-immunoprecipitate with caveolin-1 in cultured
endothelial cells [39]. If caveolin-1 expression is lost (i.e., caveolin−/−
mice), expression of Cx43, Cx40, and Cx37 are all reduced in aorta and
superior mesenteric artery, and this is coincident with impaired EDH-
dependent vasodilation and MEJ dye transfer in superior mesenteric
artery [39]. These results suggest that caveolin-1 is essential for proper
vascular connexin localization to themembrane, formationof functional
MEJ's, and normal gap junction-dependent vasodilatory responses. The
common association with caveolin-1 further supports the notion that
eNOS and connexins colocalize in the same cellular domains and exist in
the same protein complexes.
4. Potential role of nitric oxide in regulation of vascular pannexins
Pannexins are a novel protein family discovered in 2000 in the
mammalian genome based on their limited sequence homology to the
innexins, the gap junction proteins of invertebrates [67,68]. Structurally,
pannexins share a similar membrane topology with connexins, the
constitutive protein of gap junctions in vertebrates. Similarly to
connexin proteins, pannexin proteins contain four transmembrane
domains and hexamerize to form a non-selective channel at the plasma
membrane [69]. However, unlike connexins, there is currently no
evidence of gap junctions formed by the apposition of two hexamers of
pannexins, whichmay be due to the lower number of cysteine residues
on the extracellular loop of pannexins, as compared to connexins
[69,70]. There are currently 3 known isoforms of pannexins, present on
3 different regions of the genome (Panx1, Panx2 and Panx3) [67,68,71].
While Panx1 is ubiquitous, Panx2 is mostly expressed in the central
nervous systemandPanx3 is foundmainly in skin and cartilage [72]. The
functional state and the cellular distribution of pannexins seem to be
mainly regulated byglycosylation and interactionwith other pannexins,
but not by phosphorylation [69,73,74].
Functionally, it has been extensively shown that pannexins are
paracrine channels that can release purines such as ATP, however, in
theory, pannexin channels allow the passage of small molecules under
1 kDa between the cytosol and the extracellular environment [75].
The pannexin-mediated release of ATP in the extracellular milieu has
been shown to serve as a key physiological signal for intercellular
signaling as well as a signal to promote cell death [75]. Pannexin
protein plays a key role in the inﬂammatory response. For example,
pannexins have been recently identiﬁed as the channel mediating the
“ﬁnd me” signal released by apoptotic cells to recruit phagocytes in
order to clear the dying cells [76], and there is growing evidence that
Panx1 channels are involved in the secretion pathway of pro-
inﬂammatory cytokines such as IL-1β [77]. In the vasculature, a
recent study reported a role of Panx1 in the contraction of resistance
arteries where phenylephrine activates the release of vasoactives
purines, such as ATP, through Panx1 channels [78].
As previously described in this review, the nitrosylation of cysteines
has been shown to be a key element in regulating connexins, therefore,
recent effort has been directed toward understanding the importance of
cysteine residues in Panx1. Site-directed mutagenesis of cysteines
revealed that Cys346 residue is essential in the regulation of Panx1
opening as its mutation leads to a constitutively leaky channel [79].
Furthermore, when the Cys346 residue is mutated, Panx1 is hypogly-
cosylated, resulting in impaired gating of the channel [73,79,80].
Recently, several reports demonstrated opening of Panx1 channels
under oxygen and glucose deprivation in vitro, mimicking patholog-
ical conditions such as stroke [81,82]. In these conditions, the opening
of Panx1 channels led to an increase in membrane permeability,
which consequently induces neuronal degeneration. Interestingly,
during ischemia, NO production is enhanced, which induceschanges in redox potential. Although there is no direct evidence of
S-nitrosylation of cysteine residues of Panx1 during ischemic
conditions, Zhang et al. described that Panx1 channel activity is
enhanced in presence of NO donors [82]. Therefore, like the
connexins, there is potential for nitric oxide-dependent regulation
of pannexin channel function.
5. Relationship between eNOS and vascular gap junctions in disease
states
5.1. eNOS and connexins in atherosclerosis
Typically eNOS production of NO in the vasculature acts in an anti-
atherogenic manner [83]. However, during atherogenesis eNOS has
been reported to switch to production of superoxide (instead of NO)
leading to activation of reactive oxygen species (ROS) [84]. Several
physiological pathways require low levels of ROS, such as superoxide
anion, and it has been hypothesized that these may pass through gap
junctions [85,86] (for review, see Ref. [87]). Despite this, high levels of
ROS following injury (e.g. ischemia) are associated with cellular
damage, inducing lipid peroxidation of plasma membrane proteins,
DNA oxidation and nitrosylation of proteins altering cellular function. In
models of atherosclerosis, both up- and down-regulation of eNOS in
ApoE−/− (atheroprone mice) are shown to enhance the atheroscle-
rotic state [84]. In the double knockout eNOS−/−ApoE−/− mice,
atherosclerosis is advanced, suggesting a preventative role for NO
produced in atherogenesis. Yet over-expression of eNOS in ApoE−/−
mice also leads to enhanced atherosclerosis. The explanation for this
data is that eNOSswitches function fromproductionofNOtoproduction
of superoxide, leading to further cellular damage [84]. It is also possible
that secondary pathwayswhich sequester eNOSmay play a role in these
models, such as has been demonstrated for the connexins [27,47].
Connexins and their expression are integrally linked to the
progression of atherosclerosis, with associations between altered
connexin expression, signaling and hemichannel function all attrib-
uted to progression of the disease state [88,89]. Based on currently
available data, the exact mechanisms for this are not yet fully
understood.
In acute injury models such as ischemic re-perfusion insult, levels of
activated eNOS are associated with down-regulation of Cx43 with no
alterations noted in Cx37 or Cx40 [90]. Reducing eNOS in EC following
application of L-NAME does not alter Cx43 expression and has not been
shown to alter cellular proliferation or migration [90]. These data
combined with previous data showing that NO speciﬁcally nitrosylates
Cx43 [16], suggest that eNOS can induce post-translational modiﬁca-
tions of Cx43 but that thismay not be reversible following application of
NO and that this pathway is not necessarily involved in phenotypic
modulation of cells.
As mentioned previously, in vascular cell speciﬁc Cx40−/− mice,
aortic NO release (via production of eNOS) is signiﬁcantly reduced
with both Cx37 and Cx40 shown to directly interact with eNOS at
intercellular contact zones [27,47]. Separate studies have shown that
reductions in Cx40 in vascular cells leads to a recruitment of leukocyte
adhesion indicating that it is important in atherosclerotic develop-
ment [91]. Thus, the reduction in nitric oxide may be a contributing
factor to the atherogenic phenotype of the Cx40−/− mice.
Point mutations in Cx37 (C1019T mutation, encoding 319PNS) are
associated with an increase in atherogenicity in humans and in mice
[92]. While little is known about the physical structure of the Cx37 CT
and its potential binding partners, analyses show several consensus
sequences for binding partners including eNOS [47]. Using isolated
single protein analyses between the wild-type and mutated forms of
Cx37 and native eNOS peptides, this study identiﬁed that Cx37 CT can
bind with eNOS regardless of the C1019T mutation, suggesting that
both native andmutated Cx37 acts in amanner to sequester eNOS and
regulate vasomotor tone. One other possibility comes from reports
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through which Cx37 interacts with eNOS to modulate calmodulin
binding and NO production [47]. However, these previous studies do
not indicate a mechanism through which Cxs 37 and 40 mediate this
post-translational modiﬁcation, whether through sequestration in
caveloae or through direct interactions and it is not clear how loss of
connexins leads to a loss of eNOS expression. Therefore it is possible
that reductions in endothelial Cx37 could cause alterations in eNOS as
found in atherosclerosis, but does not involve the sites associated in
the known C1019T mutation.
In advanced disease states, stent placement may alter connexin and
eNOS expression leading to endothelial dysfunction. In vitro studies in
endothelial cells revealed that cells grown on stentmetal demonstrated
signiﬁcant lossof Cx43 andeNOSexpression andmaybeassociatedwith
endothelial cell dysfunction which could further the disease state
leading to stent-restenosis [93]. Therefore endothelial dysfunction in
restenosis may be mediated in part through Cx43 control of eNOS
through an as yet unknown pathway.
5.2. eNOS and connexins in hypertension
Reduction in eNOS and NO production have been associated with
endothelial dysfunction in hypertension [94,95]. Although reports in
humans have suggested that there is no deﬁnitive link between
genetic alterations in eNOS and hypertension [96]. Reductions in the
availability of NO are associated with increased pulmonary arterial
hypertension (PAH; abnormally high pressure in the pulmonary
artery due to narrowing of the pulmonary resistance arteries) in
humans, with disruptions between the interactions of eNOS and
caveolin-1 thought to reduce biologically active NO leading to PAH
(for review see Ref. [97]). Conversely, increases in the expression of
eNOS and production of NO have been associated with reductions in
blood pressure in treated hypertensive mice [98].
As previously discussed, the vascular connexins interact with both
eNOS and caveolin-1 and may play a role in hypertension. In
spontaneously hypertensive rats (SHR) treated with L-NAME (inhi-
biting NOS species), levels of endothelial Cx37 and Cx43 (but not
Cx40) are signiﬁcantly reduced, with further studies showing that in
aortic endothelium, Cx43 expression is reduced in pre-hypertensive
mice [99,100]. Levels of Cx37 and Cx43 in these mice can be rescued
following treatments with adrenergic blocker Cardovil (and to a lesser
extent atenelol) with concomitant reductions in blood pressure
(in a pathway that is independent of the adrenergic blockade).
These ﬁndings suggest that Cx43 and Cx37 are associated with
eNOS-mediated hypertension, although the pathways have yet to be
deﬁned [99].
Multiple groups have studied how vascular endothelial cell speciﬁc
deletion of Cx40 leads to hypertension in mice [101–103]. Despite the
above studies, others have suggested that only reduction in Cx40
(not Cx37 and not Cx43) are associated to hypertension in SHR as
compared to Wistar–Koyoto rats (WKR) [104]. While Cx40−/−mice
were generally considered to be hypertensive, this is not associated
with a loss of NO signaling between EC and VSMC in the resistance
arterioles, rather that renin secretion in the glomerulus is signiﬁcantly
down-regulated [102,103,105]. Despite this, earlier studies have
shown that the EC Cx40−/− knockout mice leads to dysregulated
conduction along the arteriolar beds and that this dysfunction was
independent of NO function and the renin/angiotensin system [101].
Further studies in WKR have demonstrated that Cx37 but not Cx40 or
Cx43 levels are elevated as compared to SD or SHR altered in renal
arterioles. The authors conclude that this elevated Cx37 in WKR and
that connexins in general are not associated with alterations in blood
pressure in pre-glomerular vessels [106]. Clearly, eNOS causes
alterations in hypertension although whether connexins are directly
linked to this pathway is not well deﬁned based on the current
literature.5.3. eNOS and connexins in diabetes
Enhanced production of ROS, increased degradation of NO (through
NADPH oxidases) and loss of eNOS are associated with diabetes and
insulin resistance in cells [107,108]. This suggests that eNOS activity and
NO production are integral in diabetes and insulin resistance pathways
[98]. Studies have indicated that alterations in Cx40 and 43 in efferent
arterioles may be associated with reductions in eNOS expression. Cx40
and 43 in afferent and efferent arterioles were noted to be up- and
down-regulated (respectively) in diabetic mice. In eNOS−/− mice
levels of Cx40 and Cx43 were found to be signiﬁcantly different
following diabetic induction as compared to non-treated eNOS−/−
mice. These data suggest that regulation of Cx40 and Cx43 expression in
diabetes requires the presence of eNOS to perform its function [109]. In
diabetic-induced apoE−/− mice, levels of eNOS increase with an
associated decrease in Cx37 but not other vascular connexins in small
mesenteric arteries [110]. In diabetic mice with erectile dysfunction,
reductions of eNOSwere associatedwith an increase in Cx43 expression
in penile tissue as compared to diabetic mice [111]. These data suggest
that differential regulation of vascular connexins, i.e. upregulation of
Cx40 and down-regulation of Cx37 and Cx43, may act in conjunction
with eNOS to regulate vascular function in diabetes.6. Concluding remarks
There is clear evidence that nitric oxide affects vascular gap junction
communication in vitro and in vivo, with both enhancement and
inhibition of communication reported depending on the connexins
involved and the cellular location within the vessel. While there's
evidence for S-nitrosylation as a mechanism by which nitric oxide
affects Cx43 function, theprecisemechanisms for nitric oxide regulation
of Cx37 and Cx40 are not clear. Nitric oxide's effects on Cx37 are largely
independent of cGMP signaling, so S-nitrosylation is a possibility. Nitric
oxide's effects on Cx40 seem to rely on cGMP signaling, but the precise
molecular alterations and interactions are unknown. Additionally, the
possibility of S-nitrosylation of any of the vascular connexins other than
Cx43 (Cx45, Cx40, Cx37, Cx32) or pannexin-1, has not been explored
and remains a possible regulatory mechanism. It is also unknown how
nitric oxide regulation of gap junctions may vary by cellular location
(EC-EC, SMC–SMC, MEJ) or vascular bed.
There is new evidence that not only does nitric oxide interact with
connexins, but the enzyme eNOS does as well. In endothelial cells,
eNOS can exist in a complex with at least two connexins (Cx37, Cx40)
both in vitro and in vivo, and this interaction effects eNOS function and
expression at the membrane. It is also known that loss of eNOS affects
gap junction communication in arteries, but it is unknown whether
this is due to the loss of direct interaction of connexins with eNOS or
the loss of nitric oxide signaling effects on connexins. It is clear that in
vascular disease conditions, such as atherosclerosis, hypertension, and
diabetes, both nitric oxide signaling and connexin expression and/or
function are altered. A remaining question is whether there is a
common mechanism for alteration in these pathways with each
disease condition, or is the alteration of one of the two pathways
affecting the other in sequence. Collectively, the prevailing data point
to a close interrelationship between eNOS/nitric oxide signaling and
connexin function, with the precise mechanisms of their interactions
largely undiscovered.Acknowledgements
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